Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL4155618 | 0.92 | RXFP1 (0.36) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| Butyric Acid SCHEMBL4162647 | 0.85 | RXFP1 (0.42) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| Butyric Acid SCHEMBL4166445 | 0.85 | KDM4E (0.33) | RXFP1KDM4ETP53BRD4 | |
| Butyric Acid SCHEMBL4160930 | 0.84 | RXFP1 (0.38) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL4160301 | 0.83 | KDM4E (0.32) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| Butyric Acid SCHEMBL4158045 | 0.83 | RXFP1 (0.39) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL3241772 | 0.82 | KDM4E (0.36) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL3255176 | 0.80 | HSD17B10 (0.36) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| Butyric Acid SCHEMBL4160052 | 0.80 | KDM4E (0.45) | RXFP1KDM4EUSP2ALDH1A1HPGD | |
| Butyric Acid SCHEMBL4165093 | 0.80 | KDM4E (0.41) | RXFP1KDM4EUSP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | RXFP1 3999/4885KDM4E 1970/4885USP2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.